 Marc Schneidmans Aquilo Capital Management is a San Francisco-based, healthcare-focused longshort hedge fund that was founded in 2010. The fund uses CIO Schneidmans 20 years of industry expertise in biotech research and investments, which included 15 years working at Mark Lamperts Biotechnology Value Fund, to seek out mispriced small-cap companies in the biotech sector. The funds assets under management surpassed 500 million as of August 2020. 